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Introduction
Despite the progress made in medical sciences and health 
care, morbidity and mortality following nosocomial infections 
are still commonplace. It is important to underline the role 
of opportunistic pathogens, which may be part of the normal 
human bacterial flora and cause diseases especially when the 
host immunity becomes impaired. There are serious concerns 
that untreatable pathogens may develop at an alarming rate 
in the near future. Further, in recent years, increasing rates of 
antimicrobial resistance among community and nosocomial 
pathogens has severely limited the therapeutic options for 
treating infections caused by such organisms. In view of these 
considerations, further efforts are needed to develop a new 
group of antimicrobial compounds. In recent years, there has 
been an alarming increase in life-threatening microbial infec-
tions especially in immunocompromised individuals suffering 
from acquired immune deficiency syndrome (AIDS), cancer, 
etc.1–4. Despite the development of several new antimicrobial 
agents, their clinical value is limited to  treating an increasing 
array of life-threatening systemic infections because of their 
relatively high risk of toxicity, emergence of drug resistant 
strains, pharmacokinetic differences, and/or insufficiencies 
in their antimicrobial activity.
Pyrazoles and several N-substituted pyrazoles are 
known to possess numerous chemical, biological, medici-
nal, and agricultural applications because of their versatile 
biological activities appearing as antimicrobial activity5–8, 
antitumor and antileukemia activity9, antidepressant and 
anticonvulsant activities10,11, antifungal activity12 and antitu-
bercular activity against Mycobacterium tuberculosis13. 
β-Lactamase is generally considered to be responsible for 
microbial resistance against a broad spectrum of β-lactam 
antibiotics. In 1935, Domargk showed the therapeutic value 
of a group of compounds known as sulfonamides. These are 
not specific for a special group of organisms, but are effec-
tive against a large variety of pathogenic organisms.
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Abstract
A series of novel substituted 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine benzamides 9(a–h) were 
synthesized to determine their antibacterial and antifungal activities as well as possible structure–activity relation-
ships (SARs) to improve therapeutic efficacy. The pyrazol-5-amine benzamides were screened for their antibacterial 
activity against standard strains of Gram-positive (Streptococcus pyogenes NCIM 2608, Staphylococcus aureus ATCC 
29737, Bacillus subtilis NCIM 2010) and Gram-negative (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 
20852, Klebsiella pneumoniae MTCC 618) bacteria by using streptomycin as positive control. They were also tested 
for their antifungal activities against mycotoxic strains of Fusarium verticillioides, Aspergillus ochraceous, Aspergillus 
flavus, Alternaria alternata, and Penicillium chrysogenum using nystatin as positive control. Among the synthesized 
compounds, 9d, 9g, and 9h showed potent antimicrobial activities.
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Bezenesulfonamide derivatives were also reported as 
elastase inhibitors14, carbonic anhydrase and cyclo-oxyge-
nase-2 (COX-2) inhibitors15,16, herbicides, and plant growth 
regulators17. They show affinities for endothelin ETA and ETB 
receptors in the low nanomolar range and high functional 
antagonistic potency in vitro18, and also exhibit a dual action 
to inhibit the thromboxane receptor and thromboxane syn-
thase in cardiovascular and renal diseases19. Antiproliferative, 
antiviral, and antifungal activities have been similarly evalu-
ated20. Compounds containing an amide group can alter the 
chemical properties, disposition, and biological activities of 
drugs21. Amides are currently used as antidepressants, anti-
inflammatory agents, antimalarial agents, antipsychotic 
agents, antiviral agents, steroids, and general anesthetics22. 
Amide functional groups are also found in many antibacte-
rial agents, as for example benzimidazole carboxamides, 
peptide, penicillin, cephalosporins, and thiozolidinones23.
Our earlier work on the synthesis of different heterocyclic 
systems containing high antimicrobial activity prompted 
us to synthesize a new class of heterocyclic carboxamides 
and sulfonamides and study their antibacterial activities24. 
Recently, we reported the synthesis and antimicrobial studies 
of bioactive heterocyclic sulfonamides and benzamides24–26. In 
continuation of our research work on the synthesis of bioactive 
heterocycles, the activities of the synthesized compounds were 
tested on bacterial and fungal strains by the cup-borer method, 
microwell dilution assay, and turbidometric method.
Materials and methods
Synthesis
Melting points were determined using a Selco-650 hot 
stage melting apparatus and were uncorrected. Infrared 
(IR) spectra were recorded using a Jasco FTIR-4100 series 
spectrometer. Nuclear magnetic resonance (1H NMR 
and 13C NMR) spectra were recorded on Bruker, 400 MHz 
 spectrometer using CDCl
3
 as solvent and tetramethylsilane 
(TMS) as internal standard (chemical shift in δ ppm). Spin 
multiples are given as br s (broad singlet), d (doublet), t (tri-
plet), and m (multiplet). Mass and purity were recorded on 
an LC/MSD-Trap-XCT apparatus. Elemental (CHN) analyses 
were obtained on a Vario EL III Elementar analyzer. Silica 
gel column chromatography was performed using Merck 
7734 silica gel (60–120 mesh) and Merck thin layer chroma-
tography (TLC) plates. 1-(4-Methoxybenzyl)-3-cyclopropyl-
1H-pyrazol-5-amine derivatives 9(a–h) were synthesized as 
per the method summarized in Scheme 1. Initially, mono-
Boc protected 1-(4-methoxybenzylidene) hydrazine (3) was 
synthesized by the condensation reaction of 4-methoxyben-
zaldehyde (1) with mono-Boc protected hydrazine (2). The 
subsequent double bond reduction was done using 10% 
Pd/C in ethanol, which yielded mono-Boc protected 1-(4-
methoxybenzyl) hydrazine (4). Deprotection of the amine 
group was carried out using HCl in ether, which gave the free 
amine compound (3). Finally, the key intermediate, 1-(4-
methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine (7) by 
cyclization of 1-(4-methoxybenzyl)-2-methylhydrazine salt 
(5) (1.0 g, 5.36 mol) and 3-cyclopropyl-3-oxopropanenitrile 
(6) (0.85 g, 5.36 mol) was taken in ethanol, and then sodium 
ethoxide (1.09 g, 16.0 mol) was added. The reaction mixture 
was refluxed for 2–3 h. The progress of the reaction was 
monitored by TLC. When the reaction was complete, water 
was added to the reaction mixture and extraction was done 
with ethyl acetate. The organic layer was washed with 10% 
ammonium chloride solution followed by a water wash, 
and dried with anhydrous sodium sulfate. The solvent was 
evaporated, and the crude product obtained was purified 
by column chromatography over silica gel (60–120 mesh) 
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Scheme 1. Synthesis of compounds 9(a–h). Reactions and reagent conditions: (i) EtOH/r.t, 2–3 h; (ii) 10% Pd/C/H
2
EtOAc, r.t, 3 h; (iii) dichloromethane, 
ether in HCl, 3 h; (iv) EtOH/EtCOONa, reflux 80°C, 2–3 h; (v) triethylamine, dichloromethane, 8(a–h), r.t, 4–5 h; where R-CO-Cl are: (8a) 3,5-dinitrobenzoyl 
chloride; (8b) 3-methoxybenzoyl chloride; (8c) 4-tert-butylbenzoyl chloride; (8d) 2,4-dichlorobenzoyl chloride; (8e) 4-chlorobenzoyl chloride; (8f) 
3-bromobenzoyl chloride; (8g) 2,4-difluorobenzoyl chloride; (8h) benzoyl chloride.
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using hexane:ethyl acetate (8:2) as eluent. The product 
obtained was a white crystalline solid and the yield was 
found to be 85%. 1H NMR (CDCl
3
, 400 MHz) δ: 6.95 (d, 
2H, J = 6.52 Hz, Ar-H), 6.92 (d, 2H, J = 6.2 Hz, Ar-H), 5.18 
(s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 3.95 (br s, 2H, -NH
2
), 3.85 
(s, 3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 0.71 
(m, 2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 165.4 (C), 157.7 
(C), 148.5 (C), 130.1 (2C), 128.6 (C), 114.2 (2C), 89.3 (C), 
55.9 (C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 243.3. IR 
(KBr, cm−1): 3360, 1685, 1602, 1355, 1277, 1225, 865. Anal. 
calcd. for C
14
H
17
N
3
O (in %): C-69.11; H-7.04; N-17.27. Found 
C-69.10; H-7.02; N-17.23.
The nucleophilic substitution reactions of 1-(4-
methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine (7)  
with different substituted aromatic acid chlorides 
(R-CO-Cl) (8) were carried out in the presence of tri-
ethylamine and dichloromethane (DCM) as solvents. The 
presence of an N-H proton peak at δ = 10.51 ppm in car-
boxamide 9(a-h) in proton NMR confirmed our products. 
They were also confirmed by IR data for the carboxamide 
series 9(a–h), which showed an asymmetric stretching 
frequency of R-CO-Cl in the range 1650–1710 cm−1 and 
symmetric stretching frequency at 1640–1720 cm−1. All the 
compounds obtained were in good yield with high purity. 
The structures and physical data of the synthesized mol-
ecules are tabulated in Table 1.
General procedure for the synthesis of 1-(4-
methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine 
derivatives 9(a–h)
A solution of 1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-amine (7) (1.0 eq) in dry dichloromethane was 
taken and cooled to 0–5°C in an ice bath. Triethylamine 
(3.0 eq) was added to the cold reaction mixture and stirred 
for 10 min, and different acid chlorides (1.0 eq) were added; 
the mixture was stirred at room temperature for 4–5 h and 
progress of the reaction was monitored by TLC. When the 
reaction was complete, water was added to the reaction mix-
ture and extraction was done with ethyl acetate. The organic 
layer was washed with 10% ammonium chloride solution fol-
lowed by a water wash, and dried with anhydrous sodium 
sulfate. The solvent was evaporated, and the crude product 
obtained was purified by column chromatography over silica 
gel (60–120 mesh) using hexane:ethyl acetate (8:2) as eluent. 
The product obtained was a white solid with good yield and 
high purity.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl)-3,5-dinitrobenzamide (9a) The product as a 
yellow colored solid was obtained from 1-(4-methoxybenzyl)-
3-cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
3,5-dinitrobenzoyl chloride (8a) (0.28 g, 1.13 mmol), and 
triethylamine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 11.37 (s, 1H, Ar-H), 11.27 (s, 2H, Ar-H), 10.51 (s, 1H, -NH), 
6.95 (d, 2H, J = 6.52 Hz, Ar-H), 6.92 (d, 2H, J = 6.8 Hz, Ar-H), 
5.18 (s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 3.85 (s, 3H, -OCH
3
), 
1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 0.71 (m, 2H, -CH
2
). 
13C NMR (CDCl
3
, 400 MHz) δ: 165.4 (C), 164.8 (C), 157.7 
(C), 149.4 (2C), 139.2 (C), 136.0 (C), 130.1 (2C), 128.6 (C), 
128.5 (2C), 122.1 (C), 114.2 (2C), 89.3 (C), 55.9 (C), 51.5 (C), 
9.3 (C), 8.2 (2C). MS (ESI) m/z: 437.41. IR (KBr, cm−1): 3250, 
1683, 1604, 1353, 1274, 1222, 863. Anal. calcd. For C
21
H
19
N
5
O
6
 
(in %): C-57.66; H-4.38; N-16.01. Found C-57.64; H-4.32; 
N-16.00.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl)-3-methoxybenzamide (9b) The product as a 
yellow colored solid was obtained from 1-(4-methoxybenzyl)-
3-cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
3-methoxybenzoyl chloride (8b) (0.21 g, 1.13 mmol), and 
triethylamine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 10.51 (s, 1H, -NH), 7.53 (s, 2H, Ar-H), 7.46 (s, 2H, Ar-H), 
7.33 (d, 1H, J = 7.4 Hz, Ar-H), 7.02 (d, 1H, J = 7.6 Hz, Ar-H), 6.95 
(d, 2H, J = 6.52 Hz, Ar-H), 6.92 (d, 2H, J = 6.2 Hz, Ar-H), 5.18 
(s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 3.85 (s, 3H, -OCH
3
), 3.83 (s, 
3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 0.71 (m, 
2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 165.4 (C), 164.8 (C), 
160.8 (C), 157.7 (C), 139.2 (C), 135.2 (C), 130.1 (2C), 129.9 
(C), 128.6 (C), 119.8 (C), 117.7 (2C), 114.2 (2C), 89.3 (C), 55.9 
(2C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 377.44. IR (KBr, 
cm−1): 3290, 1681, 1601, 1353, 1274, 1223, 864. Anal. calcd. for 
C
22
H
23
N
3
O
3
 (in %): C-70.01; H-6.14; N-11.13. Found C-69.01; 
H-6.04; N-11.10.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-
1H-pyrazol-5-yl)-4-tert-butylbenzamide (9c) The 
product as a yellow colored solid was obtained from 
Table 1. Chemical structures and physical data of the synthesized 
 compounds 9(a–h).
Compound R Yield (%) M.P. (°C)
9a NO2
NO2
89 254–256
9b OCH3 91 245–246
9c
CH3
CH3
CH3
88 263–265
9d Cl
Cl
85 254–255
9e
Cl
81 248–249
9f Br 84 255–258
9g F
F
79 273–275
9h 80 267–268
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1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine (7) 
(0.25 g, 1.13 mmol), 4-tert-butylbenzoyl chloride (8c) (0.24 g, 
1.13 mmol), and triethylamine (0.46 g, 3.39 mmol). 1H NMR 
(CDCl
3
, 400 MHz) δ: 10.51 (s, 1H, -NH), 7.87 (d, 2H, J = 7.9 Hz, 
Ar-H), 7.47 (s, 1H, Ar-H), 6.95 (d, 2H, J = 6.52 Hz, Ar-H), 6.92 
(d, 2H, J = 6.2 Hz, Ar-H), 5.18 (s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 
3.85 (s, 3H, -OCH
3
), 1.85 (m, 1H, -CH), 1.36 (s, 3H, -CH
3
), 1.34 
(s, 3H, -CH
3
), 1.32 (s, 3H, -CH
3
), 0.92 (m, 2H, -CH
2
), 0.71 (m, 
2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 165.4 (C), 164.8 (C), 
157.7 (C), 153.4 (C), 139.2 (C), 131.1 (C), 130.1 (2C), 128.6 (C), 
127.1 (2C), 125.2 (2C), 114.2 (2C), 89.3 (C), 55.9 (C), 51.5 (C), 
40.7 (C), 31.4 (3C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 403.52. 
IR (KBr, cm−1): 3350, 1683, 1601, 1353, 1274, 1223, 863. Anal. 
calcd. For C
25
H
29
N
3
O
2
 (in %): C-74.41; H-7.24; N-10.41. Found 
C-74.35; H-7.20; N-10.35.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl)-2,4-dichlorobenzamide (9d) The product as a 
yellow colored solid was obtained from 1-(4-methoxybenzyl)-
3-cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
2,4-dichlorobenzoyl chloride (8d) (0.25 g, 1.13 mmol), and 
triethylamine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 10.51 (s, 1H, -NH), 7.83 (s, 1H, Ar-H), 7.46 (s, 1H, Ar-H), 
7.33 (t, 1H, J = 7.4 Hz, Ar-H), 6.95 (d, 2H, J = 6.52 Hz, Ar-H), 
6.92 (d, 2H, J = 6.2 Hz, Ar-H), 5.18 (s, 1H, Ar-H), 5.02 (s, 
2H, -CH
2
), 3.85 (s, 3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 
2H, -CH
2
), 0.71 (m, 2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) 
δ: 165.4 (C), 164.8 (C), 157.7 (C), 139.2 (2C), 133.7 (C), 130.5 
(2C), 129.3 (3C), 128.6 (C), 127.1 (C), 114.2 (2C), 89.3 (C), 
55.9 (C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 416.3. IR 
(KBr, cm−1): 3320, 1683, 1601, 1353, 1272, 1223, 864. Anal. 
calcd. For C
21
H
19
Cl
2
N
3
O
2
 (in %): C-60.59; H-4.60; N-10.09. 
Found C-60.49; H-4.50; N-10.06.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl)-4-chlorobenzamide (9e) The product as a 
yellow colored solid was obtained from 1-(4-methoxybenzyl)-
3-cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
4-chlorobenzoyl chloride (8e) (0.21 g, 1.13 mmol), and tri-
ethylamine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 10.51 (s, 1H, -NH), 7.89 (d, 2H, J = 8.2 Hz, Ar-H), 7.45 
(d, 2H, J = 7.6 Hz, Ar-H), 6.95 (d, 2H, J = 6.52 Hz, Ar-H), 6.92 
(d, 2H, J = 6.2 Hz, Ar-H), 5.18 (s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 
3.85 (s, 3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 
0.71 (m, 2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 165.4 
(C), 164.8 (C), 157.7 (C), 139.2 (C), 137.7 (C), 132.3 (C), 130.1 
(2C), 129.4 (2C), 128.9 (2C), 127.6 (C), 114.2 (2C), 89.3 (C), 
55.9 (C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 381.86. IR 
(KBr, cm−1): 3364, 1683, 1600, 1353, 1273, 1222, 862. Anal. 
calcd. For C
21
H
20
ClN
3
O
2
 (in %): C-66.05; H-5.28; N-11.00. 
found C-66.02; H-5.26; N-11.03.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl)-3-bromobenzamide (9f) The product as a 
yellow colored solid was obtained from 1-(4-methoxybenzyl)-
3-cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
3-bromobenzoyl chloride (8f) (0.27 g, 1.13 mmol), and tri-
ethylamine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 10.58 (s, 1H, Ar-H), 10.51 (s, 1H, -NH), 7.89 (d, 1H, 
J = 8.2 Hz, Ar-H), 7.68 (d, 1H, J = 7.52 Hz, Ar-H), 7.33(t, 1H, 
J = 7.3 Hz, Ar-H), 6.95 (d, 2H, J = 6.52 Hz, Ar-H), 6.92 (d, 2H, 
J = 6.2 Hz, Ar-H), 5.18 (s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 3.85 (s, 
3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 0.71 (m, 
2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 165.4 (C), 164.8 (C), 
157.7 (C), 139.2 (C), 136.4 (C), 135.1 (C), 131.1 (2C), 130.1 
(2C), 128.6 (C), 126.5 (C), 123.2 (C), 114.2 (2C), 89.3 (C), 
55.9 (C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 426.31. IR 
(KBr, cm−1): 3260, 1684, 1603, 1354, 1276, 1224, 864. Anal. 
calcd. for C
21
H
20
BrN
3
O
2
 (in %): C-59.15; H-4.73; N-9.86. Found 
C-59.17; H-4.70; N-9.83.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-
1H-pyrazol-5-yl)-2,4-difluorobenzamide (9g) The 
product as a yellow colored solid was obtained from 
1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine 
(7) (0.25 g, 1.13 mmol), 2-fluorobenzoyl chloride (8g) 
(0.19 g, 1.13 mmol), and triethylamine (0.46 g, 3.39 mmol). 
1H NMR (CDCl
3
, 400 MHz) δ: 10.51 (s, 1H, -NH), 7.93 (t, 
1H, J = 7.58 Hz, Ar-H), 7.49 (t, 1H, J = 7.42 Hz, Ar-H), 7.21 
(t, 1H, J = 7.12 Hz, Ar-H), 6.95 (d, 2H, J = 6.52 Hz, Ar-H), 6.92 
(d, 2H, J = 6.2 Hz, Ar-H), 5.18 (s, 1H, Ar-H), 5.02 (s, 2H, -CH
2
), 
3.85 (s, 3H, -OCH
3
), 1.85 (m, 1H, -CH), 0.92 (m, 2H, -CH
2
), 
0.71 (m, 2H, -CH
2
). 13C NMR (CDCl
3
, 400 MHz) δ: 167.9 (C), 
165.4 (C), 164.8 (C), 159.6 (C), 157.7 (C), 139.2 (C), 130.1 (3C), 
128.6 (C), 120.7 (C), 114.2 (2C), 111.2 (C), 104.8 (C), 89.3 (C), 
55.9 (C), 51.5 (C), 9.3 (C), 8.2 (2C). MS (ESI) m/z: 365.4. IR 
(KBr, cm−1): 3260, 1685, 1602, 1355, 1277, 1225, 865. Anal. 
calcd. for C
21
H
19
F
2
N
3
O
2
 (in %): C-69.03; H-5.52; N-11.50. 
Found C-69.01; H-5.50; N-11.50.
Synthesis of N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-
pyrazol-5-yl) benzamide (9h) The product as a yellow 
colored solid was obtained from 1-(4-methoxybenzyl)-3-
cyclopropyl-1H-pyrazol-5-amine (7) (0.25 g, 1.13 mmol), 
benzoyl chloride (8h) (0.17 g, 1.13 mmol), and triethyl-
amine (0.46 g, 3.39 mmol). 1H NMR (CDCl
3
, 400 MHz) 
δ: 10.51 (s, 1H, -NH), 7.95 (d, 2H, J = 7.62 Hz, Ar-H), 7.51 (t, 
1H, J = 7.86 Hz, Ar-H), 7.44 (d, 2H, J = 7.2 Hz, Ar-H), 6.95 (d, 
2H, J = 6.52 Hz, Ar-H), 6.92 (d, 2H, J = 6.2 Hz, Ar-H), 5.18 (s, 
1H, Ar-H), 5.02 (s, 2H, -CH
2
), 3.85 (s, 3H, -OCH
3
), 1.85 (m, 
1H, -CH), 0.92 (m, 2H, -CH
2
), 0.71 (m, 2H, -CH
2
). 13C NMR 
(CDCl
3
, 400 MHz) δ: 165.4 (C), 164.8 (C), 157.7 (C), 139.2 
(C), 134.2 (C), 132.2 (C), 130.1 (2C), 129.4 (C), 128.6 (2C), 
127.5 (2C), 114.2 (2C), 89.3 (C), 55.9 (C), 51.5 (C), 9.3 (C), 
8.2 (2C). MS (ESI) m/z: 347.41. IR (KBr, cm−1): 3328, 1682, 
1601, 1352, 1274, 1223, 864. Anal. calcd. for C
21
H
21
N
3
O
2
 
(in %): C-72.60; H-6.09; N-12.10. Found C-72.58; H-6.05; 
N-12.07.
Antibacterial activity
Microorganisms used were Gram-positive (Streptococcus 
pyogenes NCIM 2608, Staphylococcus aureus ATCC 
29737, Bacillus subtilis NCIM 2010) and Gram-negative 
(Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 20852, Klebsiella pneumoniae MTCC 618) bacteria. A 
single colony of each of the cultures was inoculated in 5 mL 
of Luria–Bertani (LB) broth and incubated under shaking 
conditions overnight at 37°C. Each of the overnight cul-
tures (500 μL) was inoculated into 25 mL of LB broth and 
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incubated at 37°C at 0.2 optical density (OD; λ
max
 = 600 nm). 
Each of these cultures (500 μL) was inoculated into a coni-
cal flask containing 30 mL of nutrient broth. The contents 
of the flasks were poured into petri plates and allowed to 
solidify. The plates were appropriately labeled. On solidify-
ing, 10 wells were made on each plate using a cork-borer 
first for the negative control (dimethylsulfoxide, DMSO), 
second for the positive control (streptomycin), and the 
remaining third and fourth wells for the compounds. The 
plates were kept at room temperature for 30 min and then 
at 37°C for 24 h. After 24 h, the zone of inhibition was meas-
ured and recorded. The minimum inhibitory concentration 
(MIC) values were also determined for the microorgan-
isms that were determined as sensitive to the compound 
disk diffusion assay. The inocula of microorganisms were 
prepared from 12 h broth cultures and suspensions were 
adjusted to 0.5 McFarland standard turbidity and the 
compounds were dissolved in DMSO. MIC values of com-
pounds against each bacterial strain were determined 
based on the microwell dilution method with some modi-
fication. The 96-well plates were prepared by dispensing 
95 μL of nutrient broth and 5 μL of the inoculum into each 
well. Initially, prepared compound (100 μL) at the concen-
tration of 600 μg/mL was added into the first well. Then, 
100 μL from the serial dilution was transferred into six con-
secutive wells. The last well containing 195 μL of nutrient 
broth without compound and 5 μL of inoculum on each 
strip was used as the negative control. The final volume 
in each well was 200 μL. Streptomycin and DMSO at the 
concentration of 100 μL were prepared in nutrient broth 
and used as standard drugs for the positive and negative 
controls, respectively. The plates were covered with a ster-
ile plate sealer. The contents of each well were mixed on a 
plate shaker at 300 rpm for 30 min and then incubated at 
appropriate temperatures for 24 h. Microbial growth was 
determined by the absorbance at 610 nm using an ELx800 
universal microplate reader (Bio-Tek Instruments Inc., 
Highland Park, Vermont, USA) and confirmed by plating 
5 μL samples from clear wells on nutrient agar medium. 
The compounds used in this study were screened twice 
against each organism. The MIC was defined as the lowest 
concentration of each compound required to inhibit the 
growth of a particular organism.
Antifungal activity
Synthesized compounds were screened in vitro for their 
antifungal activities against mycotoxigenic strains of 
Fusarium verticillioides, Aspergillus ochraceous, Aspergillus 
flavus, Alternaria alternata, and Penicillium chrysogenum, 
which are capable of producing toxins that have proved 
to be toxic to both animals and plants. Potato dextrose 
agar (PDA) medium was used as the growth medium for 
F. verticillioides and A. alternata, and Czapek–Dox agar 
(CDA) medium for Aspergillus and Penicillium spp. A spore 
suspension of pathogen was prepared in 50 mL sterile 
distilled water. The spore concentration was adjusted to 
1 × 106 spores/mL using a hemocytometer. A suspension of 
2 mL was spread on PDA and CDA plates uniformly. After 
solidifying, four wells were bored in each petri plate using 
a cork borer (0.5 cm diameter). DMSO (negative control) 
in the first well, nystatin (positive control) in the second 
well, and synthesized compounds in the remaining two 
wells were taken in each plate. The plates were incubated 
at 23 ± 2°C under alternate cycles of 12/12 h NUV (near-
ultraviolet light) and darkness. After 4 days of incubation, 
plates were evaluated based on the zone of inhibition 
caused by the compounds. Compounds were screened for 
their antifungal activity at different concentrations, using 
nystatin as positive control and DMSO as negative control. 
To the culture tubes containing 1.9 mL of sterile medium, 
0.1 mL of test compound was added under sterile condi-
tions. Fresh inoculum was added to all the tubes including 
standard and controls, with a spore concentration adjusted 
to 1 × 106 spores/mL. After incubating all tubes at 37°C for 
48 h, the absorbance was recorded at 610 nm. Percentage 
inhibition was calculated according to the formula:
% Inhibition = 100(P − Q)/P
where P is absorbance without test sample and Q is absorb-
ance with test sample. The MIC was recorded in μg/mL. All 
determinant tests were performed in duplicate and the results 
are reported as the mean of these values.
Results and discussion
The synthesized compounds showed significant and moder-
ate inhibition against the bacterial strains. Among the com-
pounds 9(a–h), 9d, 9g, and 9h showed significant inhibitory 
activity (zones of inhibition in the order 9d > 9g > 9h, 4.9–
8.0 mm, 5.1–7.3 mm, and 5.8–7.2 mm, respectively) against 
bacterial strains. The remaining compounds showed mod-
erate inhibitory activity compared to the standard, strep-
tomycin. Minimum inhibitory concentration was 06 μg/mL 
against K. pneumoniae MTCC 618, 07 μg/mL against B. sub-
tilis NCIM 2010, and 09 μg/mL against P. aeruginosa ATCC 
20852. The antibacterial activities of the tested compounds 
are shown in Tables 2 and 3. As for the antifungal activity 
of compounds against the fungal pathogens, among the 
series 9(a–h), compounds 9d, 9g, and 9h showed signifi-
cant inhibitory activity in the order of 9d > 9g > 9h (zones of 
inhibition 2.3–4.4 mm, 2.3–3.5 mm, and 2.1–3.2 mm, respec-
tively). The other compounds showed moderate inhibitory 
activity compared to the standard drug, nystatin. Minimun 
inhibitory concentration for antifungal activity was 
09 μg/mL against Aspergillus ochraceous, 11 μg/mL against 
A. flavus, and 12 μg/mL against A. alternata, respectively. 
The antifungal activities of the tested compounds are shown 
in Tables 4 and 5. From the results obtained, it is evident 
that the presence of two chloro groups at the 2nd and 4th 
positions in 9d, the presence of two fluorine atoms at the 
2nd and 4th positions in 9g, and the presence of a benzoyl 
group in 9h might be the reason for the significant inhibi-
tory activity. These results confirm our previous reports27,28 
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which indicated that chlorine and fluorine atoms possess 
potent inhibitory activity. In this connection, different 
electron withdrawing groups attached to the phenyl ring 
as substituents linked to the benzoyl group were studied 
for antimicrobial efficacy. On the other hand, compound 
9g showed higher activity against bacterial strains, with an 
electron withdrawing fluorine atom at the 2nd and 4th posi-
tions. A further structure-activity relationship (SAR) study 
Table 2. Inhibition zone (diameter) in mm of synthesized compounds tested against bacterial strains.
Compound
Gram-positive bacteria Gram-negative bacteria
S. pyogenes  
NCIM 2608
B. subtilis  
NCIM 2010
S. aureus  
ATCC 29737
E. coli  
ATCC25922
P. aeruginosa  
ATCC 20852
K. pneumoniae 
MTCC 618
9a 4.1 3.6 6.2 3.5 4.7 5.9
9b 4.3 3.9 5.9 5.8 6.6 6.9
9c 3.7 3.2 — 4.2 5.4 6.1
9d 5.8 4.9 5.4 5.8 6.6 8.0
9e 5.4 3.7 5.2 5.0 6.3 6.2
9f 5.3 3.9 — 5.0 — 4.8
9g 6.2 5.1 5.9 5.8 6.4 7.3
9h 6.1 5.8 6.7 5.9 6.1 7.2
Streptomycin 5.9 4.9 5.2 5.6 6.4 5.3
Table 3. Minimum inhibitory concentration (MIC) in μg/mL of synthesized compounds tested against bacterial strains.
Compound
Gram-positive bacteria Gram-negative bacteria
S. pyogenes  
NCIM 2608
B. subtilis  
NCIM 2010
S. aureus  
ATCC 29737
E. coli  
ATCC25922
P. aeruginosa  
ATCC 20852
K. pneumoniae  
MTCC 618
9a 51 61 56 72 66 58
9b 42 51 58 54 55 58
9c 65 59 73 49 63 73
9d 33 32 37 31 39 06
9e 43 51 60 43 52 53
9f 63 50 53 77 56 53
9g 27 07 21 31 42 38
9h 29 32 35 25 09 22
Streptomycin 39 34 42 39 44 47
Table 4. Inhibition zone (diameter) in mm of synthesized compounds tested against fungal pathogens.
Compound
Microorganism used
F. verticilloides A. alternata A. flavus A. ochraceous P. chrysogenum
9a 1.6 0.9 1.2 1.4 0.9
9b 1.4 1.1 2.0 2.2 1.1
9c 1.6 1.4 2.1 1.4 1.3
9d 4.1 3.6 3.4 4.4 2.3
9e 2.9 1.2 3.4 3.2 2.1
9f 1.9 2.4 — 0.4 —
9g 3.3 2.4 2.3 3.5 2.9
9h 3.2 2.1 2.5 3.2 2.1
Nystatin 1.7 1.4 2.1 2.1 1.9
Table 5. Minimum inhibitory concentration (MIC) in µg/mL of synthesized compounds tested against fungal pathogens.
Compound
Microorganism used
F. verticilloides A. alternata A. flavus A. ochraceous P. chrysogenum
9a 56 29 42 54 59
9b 54 51 50 22 41
9c 46 44 41 34 43
9d 13 14 23 09 39
9e 19 12 54 32 41
9f 49 34 — 44 —
9g 18 20 11 24 21
9h 21 12 31 32 23
Nystatin 32 24 37 39 39
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revealed that compound 9h, without a substituent on the 
phenyl ring, also showed relatively significant inhibitory 
activity. We have briefly investigated the different SARs of 
the carboxamide 9(a-h) functionalized derivatives with 
different groups added on the phenyl ring. These modifica-
tions change the potency of the antibacterial and antifungal 
activity profile of the synthesized compounds.
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